8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934 

Date of report (Date of earliest event reported):  September 2, 2009

SKYSTAR BIO-PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in Charter)

Nevada	000-28153	33-0901534
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(IRS Employer Identification No.)

Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South,

Gaoxin District, Xi’an, Shaanxi Province, P.R. China

(Address of Principal Executive Offices)

(8629) 8819-3188

 (Issuer Telephone Number)

N/A

 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On September 2, 2009, Skystar Bio-Pharmaceutical Company issued a press release announcing that it has been awarded a High Technology Enterprise Certificate by the Shaanxi Provincial Government. A copy of the press release is attached as Exhibit 99.1, and the information in Exhibit 99.1 is incorporated herein by reference.

The information in Item 8.01 and Item 9.01(d) in this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d)   Exhibits

Exhibit Number	Description
99.1	Press Release dated September 2, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: September 2, 2009	Skystar Bio-Pharmaceutical Company (Registrant)
	By:	/s/ Bennet P. Tchaikovsky
		Bennet P. Tchaikovsky
		Chief Financial Officer

EX-99.1

Exhibit 99.1

Skystar Bio-Pharmaceutical Awarded High Technology Enterprise Certificate

Preferential Income Tax Rate Extended through 2011

XI'AN, CHINA, September 2, 2009 — Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI) ("Skystar" or the “Company”), a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that the Company was awarded a High Technology Enterprise Certificate (“Certificate”) from the Shaanxi Province Ministry of Science and Technology, Shaanxi Province Ministry of Finance and Shaanxi Province State Administration of Taxation. This Certificate extends Skystar's 15% preferential income tax rate, rather than the statutory 25% tax rate, through December 31, 2011. The Company can extend the Certificate from January 1, 2012 through December 31, 2014. For the period beginning January 1, 2015 the Company will need to go through a re-certification process to keep the Certificate.

High Technology Enterprise Certificates are awarded to qualified enterprises that meet the following criteria: developing core intellectual property rights, receiving over 60% of their annual revenues from high-technology products/services, and perform highly technical research and development. Skystar initially received the Certificate in 2000 and has since received the 15% preferential tax rate.

“The criteria for obtaining this Certificate have become increasingly difficult,” said Weibing Lu, Skystar’s Chairman and Chief Executive Officer.  “However, our continued compliance with these evolving standards further validates our commitment to bringing new products to market and executing an effective R&D strategy. We are proud of the continuing recognition by the Chinese government for our contributions to China’s animal farming industry as we continue to grow our business. Skystar is executing on its immediate strategy to meet its 2009 objectives of 40 new product approvals, as well as complete the expansion of two production facilities to meet the growing demand for our products.”

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 170 products, with over 40 additional products in the developmental stage. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.

To be added to the Company's email distribution for future news releases, please send your request to skystar@tpg-ir.com.

Forward-looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

Contacts

The Piacente Group, Inc. (Investor Relations Counsel)

     Brandi Floberg

     (212) 481-2050

     skystar@tpg-ir.com

Skystar Bio-Pharmaceutical Company

     Scott Cramer

     Director - - U.S. Representative

     (407) 645-4433

     scramer@skystarbio-pharmaceutical.com

# # #